The Role of Klotho Beta in Colorectal Cancer Tumorigenesis

Klotho Beta 在结直肠癌肿瘤发生中的作用

基本信息

  • 批准号:
    10394706
  • 负责人:
  • 金额:
    $ 3.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-04 至 2024-01-03
  • 项目状态:
    已结题

项目摘要

Abstract Colorectal cancer (CRC) is both the third most common and deadliest cancer in the United States. Despite recent advances in treatment, the 5-year survival rate remains poor due to multiple factors including delayed diagnosis, chemoresistance, and disease heterogeneity. Altered expression of enteroendocrine protein signaling components consisting of Fibroblast Growth Factor Receptor 4 (FGFR4), its ligand Fibroblast Growth Factor 19 (FGF19), and co-receptor Klotho Beta (KLB) recently have been implicated in various cancers. Specific to CRC, the role of KLB remains elusive, although FGF19 and FGFR4 have more established oncogenic functions. An objective of this proposed research is to delineate KLB’s function in CRC. The work is predicated on the analysis of CRC RNA-seq data from The Cancer Genome Atlas (TCGA) database consistently showing significant repression in CRC generally and across all subtypes. Collectively, it is necessary to further investigate and validate KLB’s role in CRC, focusing on how KLB modulates oncogenic FGFR4-FGF19 signaling in the larger context of epithelial-mesenchymal transition (EMT) and tumorigenesis. Thus, our overall hypothesis is that KLB demonstrates tumor suppressor properties in CRC by negatively regulating oncogenic, EMT-promoting FGFR4-FGF19 signaling. Specific Aim 1 will test the hypothesis by analyzing detailed clinical parameters via informatics to assess the prognostic value of KLB deficiency in CRC and reveal its impact on tumor dynamics in vitro and in vivo. Our preliminary data reveals tumor-suppressor-like properties of KLB as its expression is directly associated with treatment success, microsatellite stability, survivability and inversely with pathologic stage. Additionally, KLB downregulation occurs as early as the adenoma stage further supported by a CRC cell line panel showing global KLB repression which directly correlated with differentiation status. Finally, KLB expression was enhanced in two separate in vitro CRC models of differentiation and its transgenic overexpression was associated with increased cellular organization and polarization of HT29 cells compared to CrisprCas9-induced knock down. Specific Aim 2 will investigate KLB’s mechanism of action by testing FGFR4-FGF19 signaling as the major effector pathway through which KLB affects CRC. In support of this Aim, we present compelling new preliminary evidence showing that KLB expression positively correlates with Farnesoid-X-Receptor (FXR), a known tumor suppressor and target of FGFR4 signaling, within the clinical data thereby indicating possible crosstalk. Additionally, chemical agonism of FXR induces KLB expression in Caco2 cells in vitro. By performing these studies, we expect to (i) Establish KLB’s clinical implications in CRC, and (ii) Demonstrate that KLB affects CRC mechanistically through regulation of FGFR4-FGF19 signaling. Overall, this study will establish a tentative role for KLB in CRC and how its presence impacts oncogenic FGFR4-FGF19 signaling. The ultimate goal of this proposal is to utilize KLB expression to predict prognosis, treatment response and serve as a potential therapeutic target for improving CRC patient outcomes.
摘要 结直肠癌(CRC)是美国第三大最常见和最致命的癌症。尽管最近 治疗的进步,5年生存率仍然很低,由于多种因素,包括延迟诊断, 化学抗性和疾病异质性。肠内分泌蛋白信号传导的表达改变 由成纤维细胞生长因子受体4(FGFR 4)及其配体成纤维细胞生长因子19组成的成分 最近,FGF 19和共受体Klotho Beta(KLB)已经涉及各种癌症。具体到CRC, 尽管FGF 19和FGFR 4具有更确定的致癌功能,但KLB的作用仍然难以捉摸。一个 本研究的目的是阐明KLB在CRC中的作用。这项工作是以分析为基础的 来自癌症基因组图谱(TCGA)数据库的CRC RNA-seq数据一致显示, 在CRC中普遍存在抑制,并跨越所有亚型。总的来说,有必要进一步调查, 验证KLB在CRC中的作用,重点是KLB如何调节较大肿瘤细胞中的致癌FGFR 4-FGF 19信号传导。 上皮-间质转化(EMT)和肿瘤发生的背景。因此,我们的总体假设是,KLB 在CRC中通过负调节致癌、EMT促进 FGFR 4-FGF 19信号传导。具体目标1将通过分析详细的临床参数来检验假设, 信息学评估KLB缺陷在CRC中的预后价值,并揭示其对肿瘤动力学的影响。 体外和体内。我们的初步数据揭示了KLB的肿瘤抑制样特性,因为它的表达是直接的。 与治疗成功率、微卫星稳定性、生存率相关,与病理分期呈负相关。 此外,KLB下调早在腺瘤阶段就发生,进一步得到CRC细胞系的支持 显示与分化状态直接相关的整体KLB抑制的图。最后,KLB表达式 在两种不同的体外大肠癌分化模型中, 与CrisprCas 9诱导的HT 29细胞相比, 打倒。具体目标2将通过测试FGFR 4-FGF 19信号传导来研究KLB的作用机制, KLB影响CRC的主要效应途径。为了支持这一目标,我们提出了令人信服的新 初步证据显示KLB表达与法尼醇X受体(FXR)正相关, 已知的肿瘤抑制因子和FGFR 4信号传导的靶点,在临床数据中,从而表明可能的 串话。此外,FXR的化学激动剂在体外诱导Caco 2细胞中的KLB表达。通过执行 这些研究,我们希望(i)建立KLB在CRC中的临床意义,(ii)证明KLB影响 CRC通过调节FGFR 4-FGF 19信号传导机制。总体而言,本研究将建立一个初步的 KLB在CRC中的作用及其存在如何影响致癌FGFR 4-FGF 19信号传导。这最终的目的 建议利用KLB表达来预测预后、治疗反应并作为潜在的 用于改善CRC患者结局的治疗目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael W Rohr其他文献

The dietary peroxidized lipid, 13-HPODE, promotes intestinal inflammation by mediating granzyme B secretion from natural killer cells.
饮食中的过氧化脂质 13-HPODE 通过介导自然杀伤细胞分泌颗粒酶 B 来促进肠道炎症。
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Michael W Rohr;C. Narasimhulu;Esra'a Keewan;Simran Hamid;S. Parthasarathy
  • 通讯作者:
    S. Parthasarathy

Michael W Rohr的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael W Rohr', 18)}}的其他基金

The Role of Klotho Beta in Colorectal Cancer Tumorigenesis
Klotho Beta 在结直肠癌肿瘤发生中的作用
  • 批准号:
    10534203
  • 财政年份:
    2021
  • 资助金额:
    $ 3.23万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.23万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了